UW19029
OPEN TO ACCRUAL
P2- 5FU, oxaliplatin, nal-IRI & immunotherapy (+ trastuzumab for HER2+) for adv esophageal & gastric
S2303
OPEN TO ACCRUAL
Adding Nivolumab to Usual Treatment for People with Advanced Stomach or Esophageal Cancer
UW24158
OPEN TO ACCRUAL
P2 Safety & Efficacy of Raludotatug Deruxtecan Participants With GI Cancers